Assessing treatment outcomes in CLAD: The Hannover-extracorporeal photopheresis model
- PMID: 37071121
- DOI: 10.1016/j.healun.2022.09.022
Assessing treatment outcomes in CLAD: The Hannover-extracorporeal photopheresis model
Abstract
Background: Chronic lung allograft dysfunction (CLAD) is a leading cause of graft loss in lung transplantation. Despite this, convincing treatment data is lacking, and protocols vary widely between centers. CLAD phenotypes exist, but phenotype transitioning has increased the challenge of designing clinically relevant studies. Extracorporeal photopheresis (ECP) has long been a suggested salvage treatment, but efficacy appears unpredictable. This study describes our experiences with photopheresis, using novel temporal phenotyping to illustrate the clinical course.
Methods: Retrospective analysis of patients completing ≥3 months of ECP for CLAD between 2007 and 2022 was performed. A latent class analysis employing a mixed-effects model was performed, deriving patient subgroups based on spirometry trajectory over the 12 months prior to photopheresis until graft loss or 4 years post photopheresis initiation. The resulting temporal phenotypes were compared in terms of treatment response and survival outcomes. Linear discriminatory analysis was used to assess phenotype predictability, relying solely on data available at photopheresis initiation.
Results: Data from 5,169 outpatient attendances in 373 patients was used to construct the model. Five trajectories were identified, with uniform spirometry changes evident following 6 months of photopheresis. Outcomes were poorest in Fulminant patients (N = 25, 7%) with median survival of 1 year. In the remainder, poorer lung function at initiation led to poorer outcomes. The analysis revealed important confounders, affecting both decision-making and outcome interpretation.
Conclusions: Temporal phenotyping provided novel insights into ECP treatment response in CLAD, particularly the importance of timely intervention. Limitations in % Baseline values in guiding treatment decisions warrant further analysis. Photopheresis may have a more uniform effect than previously thought. Predicting survival at ECP initiation appears feasible.
Keywords: CLAD; lung transplant; mixed-modelling; phenotypes; photopheresis.
Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure statement MG has previously received speaker fees from Therakos. Neither Therakos nor any of their partners were involved or indeed had any prior knowledge of the manuscript at any stage prior to publication. JMM reports institutional grants and speaker fees from Boehringer Ingelheim. FI reports consulting and speaker fees as well as travel support grants from Biotest AG. TW has received research grants from the German Ministry for Research and Education for projects unrelated to this manuscript. None of the other authors reported any relevant financial interests.
Similar articles
-
Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.J Clin Apher. 2024 Jun;39(3):e22128. doi: 10.1002/jca.22128. J Clin Apher. 2024. PMID: 38829041
-
Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.Am J Transplant. 2013 Apr;13(4):911-918. doi: 10.1111/ajt.12155. Epub 2013 Feb 13. Am J Transplant. 2013. PMID: 23406373
-
Lung transplant recipients on long-term extracorporeal photopheresis.Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13041. Epub 2017 Aug 1. Clin Transplant. 2017. PMID: 28653398
-
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation.Transplantation. 2018 Jul;102(7):1059-1065. doi: 10.1097/TP.0000000000002168. Transplantation. 2018. PMID: 29557913 Free PMC article. Review.
-
Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: An emerging therapeutic approach?Transfus Apher Sci. 2017 Feb;56(1):17-19. doi: 10.1016/j.transci.2016.12.010. Epub 2017 Jan 13. Transfus Apher Sci. 2017. PMID: 28094112 Review.
Cited by
-
A novel web-based tool for lung transplant patients undergoing extracorporeal photopheresis.JHLT Open. 2024 May 10;5:100106. doi: 10.1016/j.jhlto.2024.100106. eCollection 2024 Aug. JHLT Open. 2024. PMID: 40143912 Free PMC article.
-
Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.Transplantation. 2025 Mar 1;109(3):454-466. doi: 10.1097/TP.0000000000005162. Epub 2024 Aug 6. Transplantation. 2025. PMID: 39104003 Review.
-
Exosomal-miRNas expression and growth factors released by mononuclear cells of CLAD patients in response to extracorporeal photopheresis.J Transl Med. 2024 Mar 14;22(1):276. doi: 10.1186/s12967-024-05045-6. J Transl Med. 2024. PMID: 38486224 Free PMC article.
-
One versus two: How much does it matter? A single-center retrospective study evaluating 1-day extracorporeal photopheresis schedule for treating patients with chronic lung allograft rejection.Transfusion. 2025 Aug;65(8):1490-1501. doi: 10.1111/trf.18318. Epub 2025 Jul 14. Transfusion. 2025. PMID: 40657687 Free PMC article.
-
A European Multi-Center Analysis of Extracorporeal Photopheresis as Therapy for Chronic Lung Allograft Dysfunction.Transpl Int. 2024 Jan 12;36:11551. doi: 10.3389/ti.2023.11551. eCollection 2023. Transpl Int. 2024. PMID: 38282747 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical